A Novel Tumour Suppressor Function Of E2F7 In Squamous Cell Carcinoma Formation
Funder
National Health and Medical Research Council
Funding Amount
$524,124.00
Summary
squamous cell carcinomas of the skin are the second most common skin cancer. In this proposal we present data showing that a new gene, E2F7, may play an important role in the development of squamous cell carcinoma. If true, these studies will identify a new therapeutic target that could be exploited in developing novel anticancer therapies.
Kidskin: An Intervention To Reduce Sun Exposure In Children
Funder
National Health and Medical Research Council
Funding Amount
$307,775.00
Summary
Melanoma is an important public health problem in Australia. Almost all melanoma is caused by exposure to sunlight, and childhood exposure appears to be particularly important. Thus, if we can reduce childhood exposure, we should ultimately be able to reduce the incidence of melanoma. Despite nation-wide campaigns such as SunSmart, children in Australia still get too much sun exposure. The school offers an ideal opportunity for implementing sun-safety campaigns in children. In 1995, we began the ....Melanoma is an important public health problem in Australia. Almost all melanoma is caused by exposure to sunlight, and childhood exposure appears to be particularly important. Thus, if we can reduce childhood exposure, we should ultimately be able to reduce the incidence of melanoma. Despite nation-wide campaigns such as SunSmart, children in Australia still get too much sun exposure. The school offers an ideal opportunity for implementing sun-safety campaigns in children. In 1995, we began the Kidskin study, which aims to develop, implement and test a school-based program to reduce sun exposure. Preliminary data from the study show that we successfully reduced exposure. However, we are not certain that we have reduced their risk of melanoma. To see if we have reduced the risk of melanoma, we are counting the children's moles. Moles are strongly related to melanoma, and are our best way of measuring actual risk of melanoma. If we are successful, it will be the first time anyone has shown that reducing exposure to sunlight during childhood will lead to a reduction in the incidence of melanoma in later life.Read moreRead less
Novel Tools For The Imaging Of Tumor Hypoxia Using PET
Funder
National Health and Medical Research Council
Funding Amount
$727,856.00
Summary
Fast growing tumors often outgrow the ability of blood vessels to properly supply them with nutrients and oxygen. This creates tissue areas within the tumor that are lacking oxygen and are highly resistant to radiotherapy and chemotherapy. Imaging these areas using nuclear medicine techniques has now become important for therapy planning of cancer sufferers. This project aims to improve the properties of the existing agents in order to better select patients for a particular type of treatment.
Development Of Novel EGFR Tyrosine Kinase Inhibitors For The Management Of Glioma, Head And Neck And Other Cancers
Funder
National Health and Medical Research Council
Funding Amount
$196,527.00
Summary
Abnormalities in EGF-EGFR family signalling pathways have been implicated in many human cancers including glioma, squamous cell carcinome of the head and neck, colon, ovary and prostate, and are associated with poor clinical prognosis, non-responsiveness to chemotherapy, and decreased survival. Inhibitors of these pathways would therefore be useful anti-cancer pharmaceuticals. This proposal outlines experiments aimed at understanding the role of the individual EGFR family members in controlling ....Abnormalities in EGF-EGFR family signalling pathways have been implicated in many human cancers including glioma, squamous cell carcinome of the head and neck, colon, ovary and prostate, and are associated with poor clinical prognosis, non-responsiveness to chemotherapy, and decreased survival. Inhibitors of these pathways would therefore be useful anti-cancer pharmaceuticals. This proposal outlines experiments aimed at understanding the role of the individual EGFR family members in controlling a complex signalling network, and the development of novel small molecule inhibitors of these pathways which are specific for individual EGFR family members and which should prove effective in the management of many forms of cancer. Additionally, the potential synergy of these inhibitors in combination therapy with other anti-cancer drugs and reagents which induce cell death will be investigated. These small molecule pharmaceuticals could easily be produced commercially, and taken into clinical trials, in Australia.Read moreRead less
E2F Inhibitors As Anticancer Agents For Squamous Cell Carcinoma
Funder
National Health and Medical Research Council
Funding Amount
$257,036.00
Summary
Squamous cell carcinoma of the head and neck is one of the six most frequent causes of cancer death worldwide. these tumours are currently treated with surgery, radiotherapy and chemotherapy. Although these treatments are associated with a five year survival rate of between 40% and 60% there is a critical need for more effective and less destructive treatments. In this application we will extend on our earlier work in which we identified the protein E2F1 as being a major contributor to tumour de ....Squamous cell carcinoma of the head and neck is one of the six most frequent causes of cancer death worldwide. these tumours are currently treated with surgery, radiotherapy and chemotherapy. Although these treatments are associated with a five year survival rate of between 40% and 60% there is a critical need for more effective and less destructive treatments. In this application we will extend on our earlier work in which we identified the protein E2F1 as being a major contributor to tumour development. In normal cells, E2F1 is required for the regulated growth of head and neck cells. However, we found that in head and neck tumours, E2F1 is overactive and contributes to the dergulated growth of the tumour. In this project we will test our newly developed inhibitors of E2F1 on various tumour cells derived from head and neck cancers to see how effective they are at stopping tumour cell growth. Furthermore we will test these compounds in animal models of head and neck cancer to determine whether they will be useful therapeutic agents for treatment of human cancer. Early results on tumour cell lines look very promising.Read moreRead less